Status:
RECRUITING
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Postoperative Delirium
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. The the primary hypothesis is that...
Detailed Description
The investigators will be required to attend the professional training before recruitment and strictly adhere to the study protocol. All the raw data will be recorded in the case report forms. Data wi...
Eligibility Criteria
Inclusion
- Patients with temporal glioma scheduled for a elective craniotomy
- Age ≥18 years
- Obtain written informed consent.
Exclusion
- Patients with severe preoperative cognitive impairment
- History of traumatic brain injury or previous neurosurgery
- History of psychotropic medications
- Allergy to dexmedetomidine
- Pregnant or lactating women
- History of obstructive sleep apnoea syndrome
- Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
- Severe hepatic dysfunction
- Severe renal dysfunction
Key Trial Info
Start Date :
January 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT06164314
Start Date
January 25 2024
End Date
September 30 2026
Last Update
February 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital
Beijing, China